Vudalimab - CAS 2329669-72-7

Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors.

PD-1/PD-L1

Immunology/Inflammation, Apoptosis, Cell Cycle/Checkpoint

2329590

-20°C

Ice Packs

Inhibitory Antibodies